Abstract
Lurasidone [(3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]cyclohexylmethyl}hexahydro-4,7-methano-2H-isoindole-1,3-dione hydrochloride; SM-13496] is an azapirone derivative and a novel antipsychotic candidate. The objective of the current studies was to investigate the in vitro and in vivo pharmacological properties of lurasidone. Receptor binding affinities of lurasidone and several antipsychotic drugs were tested under comparable assay conditions using cloned human receptors or membrane fractions prepared from animal tissue. Lurasidone was found to have potent binding affinity for dopamine D2, 5-hydroxytryptamine 2A (5-HT2A), 5-HT7, 5-HT1A, and noradrenaline α2C receptors. Affinity for noradrenaline α1, α2A, and 5-HT2C receptors was weak, whereas affinity for histamine H1 and muscarinic acetylcholine receptors was negligible. In vitro functional assays demonstrated that lurasidone acts as an antagonist at D2 and 5-HT7 receptors and as a partial agonist at the 5-HT1A receptor subtype. Lurasidone showed potent effects predictive of antipsychotic activity, such as inhibition of methamphetamine-induced hyperactivity and apomorphine-induced stereotyped behavior in rats, similar to other antipsychotics. Furthermore, lurasidone had only weak extrapyramidal effects in rodent models. In animal models of anxiety disorders and depression, treatment with lurasidone was associated with significant improvement. Lurasidone showed a preferential effect on the frontal cortex (versus striatum) in increasing dopamine turnover. Anti-α1-noradrenergic, anticholinergic, and central nervous system (CNS) depressant actions of lurasidone were also very weak. These results demonstrate that lurasidone possesses antipsychotic activity and antidepressant- or anxiolytic-like effects with potentially reduced liability for extrapyramidal and CNS depressant side effects.
Footnotes
This research was supported by Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan.
Disclosure/conflict of interest: All authors were full-time employees of Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan, when this study was conducted.
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
doi:10.1124/jpet.110.167346.
-
ABBREVIATIONS:
- SM-13496
- (3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]cyclohexylmethyl}hexahydro-4,7-methano-2H-isoindole-1,3-dione hydrochloride
- 5-HT
- 5-hydroxytryptamine
- APO
- apomorphine
- CAR
- conditioned avoidance response
- CNS
- central nervous system
- DOPAC
- 3,4-dihydroxyphenylacetic acid
- EPS
- extrapyramidal side effects
- FRT
- forepaw retraction time
- MAP
- methamphetamine
- MED
- minimum effective dose
- p-CAMP
- p-chloroamphetamine
- TRY
- tryptamine
- MK-801
- (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate
- 8-OH-DPAT
- 8-hydroxy-2-(di-N-propylamino)tetralin) hydrobromide
- WB4101
- 2-[2-(2,6-dimethoxyphenoxy)ethylaminomethyl]-1,4-benzodioxane
- CHO
- Chinese hamster ovary
- US
- unconditioned stimulus
- NMDA
- N-methyl-d-aspartate
- SB-269970
- (2R)-1-[(3-hydroxyphenyl)sulfonyl]-2-(2-(4-methyl-1-piperidinyl)ethyl)pyrrolidine
- SSRI
- serotonin reuptake inhibitor
- SD
- Sprague-Dawley.
- Received February 18, 2010.
- Accepted April 16, 2010.
- Copyright © 2010 by The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|